Last reviewed · How we verify
Bivalent rLP2086 Vaccine
The bivalent rLP2086 vaccine is a vaccine that targets multiple strains of the SARS-CoV-2 virus.
The bivalent rLP2086 vaccine is a vaccine that targets multiple strains of the SARS-CoV-2 virus. Used for Prevention of COVID-19 caused by SARS-CoV-2.
At a glance
| Generic name | Bivalent rLP2086 Vaccine |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
It works by inducing an immune response against the virus, providing protection against severe illness and hospitalization. The vaccine is designed to be effective against multiple variants of the virus, including Omicron and Delta. This is achieved through the use of a bivalent design, which combines two different strains of the virus into a single vaccine.
Approved indications
- Prevention of COVID-19 caused by SARS-CoV-2
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (PHASE2)
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
- A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years (PHASE2)
- A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. (PHASE2)
- Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. (PHASE2)
- A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years (PHASE2)
- A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age (PHASE2)
- Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bivalent rLP2086 Vaccine CI brief — competitive landscape report
- Bivalent rLP2086 Vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI